

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 80 Robinson Road, #02-00, Singapore 068898

March 5, 2019

Singapore Exchange Securities Trading Limited

11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sirs,

Sub: Issuance of rated unsecured bonds of US\$200 million under Regulation S of the U.S. Securities Act of 1933, as amended.

Further to the disclosures made to the stock exchange earlier in this regard, we wish to inform you that the Company has successfully completed today i.e. March 5, 2019, the issuance of rated unsecured bonds (the "Notes") to institutional investors under Regulation S of the U.S. Securities Act of 1933, as amended, bearing interest at 6.00% per annum. The Notes were issued at par in a principal amount of US\$200 million and will mature in March, 2024.

The Joint Global Coordinators, Joint Lead Managers and Joint Bookrunners to the issue of the Notes are DBS Bank Ltd., J.P. Morgan (S.E.A.) Limited and UBS AG, Singapore Branch.

The above is for your information and records. The Company will provide further updates in this regard, if and when necessary.

We request you to take the same on record.

This notice is not for distribution in or into the United States. This notice is not an offer for sale of any securities in the United States or any jurisdiction. Securities may not be offered or sold in the United States or any jurisdiction absent registration or an exemption from registration under applicable laws and regulations. Any public offering of securities to be made in the United States would be made by means of a prospectus that would contain detailed information about the issuer, their management and their financial statements in compliance with all relevant laws. The issuer does not have any current intention to make any public offering of, or to register, any securities in the United States.

Thanking you,

Yours Faithfully,
For Jubilant Pharma Limited



Arun Kumar Sharma
Chief Financial Officer